|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
Laboratory Report
|
|
|
|||||||||||||||||||||||||
Hematology
| Test | 29-APR-2023 | Reference Range | Unit |
|---|---|---|---|
| Leukocytes [#/volume] in Blood by Automated count | 4.0 | 4.0 - 11.0 | 10*3/uL |
| Erythrocytes [#/volume] in Blood by Automated count | 4.3 | 3.8 - 5.1 | 10*6/uL |
| Hemoglobin [Mass/volume] in Blood | 12.9 | 12 - 16 | g/dL |
| Hematocrit [Volume Fraction] of Blood by Automated count | 44.2 | 36 - 46 | % |
| MCV [Entitic mean volume] in Red Blood Cells by Automated count | 80.3 | 80 - 100 | fL |
| MCH [Entitic mass] by Automated count | 27.6 | 27 - 33 | pg |
| MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count | 32.9 | 32 - 36 | g/dL |
| Erythrocyte [DistWidth] in Blood by Automated count | 12.6 | 11.5 - 14.5 | % |
| Platelets [#/volume] in Blood by Automated count | 134.3 L | 150 - 450 | 10*3/uL |
Chemistry
| Test | 29-APR-2023 | Reference Range | Unit |
|---|---|---|---|
| Glucose [Mass/volume] in Serum or Plasma | 98.9 | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Serum or Plasma | 14.0 | 7 - 18 | mg/dL |
| Creatinine [Mass/volume] in Serum or Plasma | 2.6 H | 0.5 - 1.1 | mg/dL |
| Calcium [Mass/volume] in Serum or Plasma | 8.6 | 8.6 - 10.3 | mg/dL |
| Sodium [Moles/volume] in Serum or Plasma | 143.8 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Serum or Plasma | 4.9 | 3.5 - 5.1 | mmol/L |
| Chloride [Moles/volume] in Serum or Plasma | 107.3 | 98 - 110 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25.9 | 22 - 32 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 6.3 L | 6.6 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 4.4 | 3.5 - 5.0 | g/dL |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 8.6 H | 0.1 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 105.2 H | 32 - 91 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 35.9 | 7 - 56 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26.3 | 10 - 40 | U/L |
| Magnesium [Mass/volume] in Blood | 2.1 | 1.7 - 2.2 | mg/dL |
| Cholesterol [Mass/volume] in Serum or Plasma | 293.9 H | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 110.3 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 115.6 H | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 24.6 L | 40 - 60 | mg/dL |
| Hemoglobin A1c/Hemoglobin.total in Blood | 6.3 H | 4.8 - 5.9 | % |
| Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Blood by Immunoassay | 1.8 | 0 - 125 | pg/mL |
| Troponin I.cardiac [Mass/volume] in Serum or Plasma by High sensitivity method | 110.4 H | 0 - 19.9 | ng/L |
Coagulation
| Test | 29-APR-2023 | Reference Range | Unit |
|---|---|---|---|
| INR in Platelet poor plasma by Coagulation assay | 0.9 | 0.9 - 1.1 | {INR} |
| aPTT in Blood by Coagulation assay | 32.2 | 25 - 35 | s |
Annotation
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows evidence of chronic kidney dysfunction (elevated creatinine), cholestasis or possible liver dysfunction (markedly elevated total bilirubin and alkaline phosphatase), mild thrombocytopenia, hypoalbuminemia, and dyslipidemia (high total/LDL cholesterol, low HDL). HbA1c is elevated, indicating suboptimal glycemic control. Cardiac marker troponin I is significantly elevated, suggesting possible acute or chronic myocardial injury. Prompt clinical correlation and further evaluation of renal, hepatic, and cardiac status are recommended. |